skip to Main Content

2022 Programme Speakers

Allen, P

Peter Allen
Duke Cancer Center


Dr. Peter J. Allen is Professor of Surgery and Chief of the Division of Surgical Oncology Division at Duke University. He also serves as the Chief of Surgery at the Duke Cancer Institute.

He is originally from the state of Maine, received his undergraduate degree from Harvard University, and his medical degree from Dartmouth. Dr Allen performed his general surgical residency at Walter Reed Army Medical Center in Washington D.C., and performed both research and clinical fellowships at Memorial Sloan Kettering. Following his training, he returned to Walter Reed where he practiced general surgical oncology. During his time as a surgical attending at Walter Reed, Dr. Allen was deployed to Iraq where he spent one year as a surgeon on a forward surgical team and was awarded the combat medical badge. Dr. Allen was recruite4d to Memorial Sloan-Kettering Cancer Center in 2003, and for 13 years he led the surgical efforts in the treatment of neoplastic diseases of the pancreas. During his time at Sloan Kettering, Dr. Allen held the Murray F Brennan Chair in Surgery and served as the Vice Chair for Surgical Services and the Associate Director for Clinical programs in the Rubenstein Center for Pancreatic Research.

Dr. Allen joined the Duke team in 2018 as the chief of the Division of Surgical Oncology, and the Chief of Surgery in the Duke Cancer Institute. His clinical and research efforts have been focused on the development of novel diagnostic and therapeutic approaches to invasive and pre-invasive lesions of the pancreas, with a particular focus on intraductal papillary mucinous neoplasms. His research has been funded by numerous organizations and he has maintained NIH funding since 2009.


Luca Aldrighetti
San Raffaele Hospital



De Boer, M

Marieke de Boer
University Medical Center Groningen
the Netherlands


Marieke T de Boer, MD PhD, consultant HPB and Liver Transplant surgeon University Medical Center Groningen. Special interest: Living donor liver transplantation, complex liver surgery and minimally invasive HPB surgery.

Besselink, M

Marc Besselink
Amsterdam University Medical Centers
the Netherlands


Marc Besselink (1976) is the professor of Pancreatic and Hepatobiliary (HPB) surgery at Amsterdam UMC, the Netherlands. He studied at Utrecht University (Medicine) and Oxford University (Evidence Based Health Care). In 2002, he was one of the founders of the Dutch Pancreatitis Study Group, in 2012 the Dutch Pancreatic Cancer Group, and in 2016 the European Consortium on Minimally Invasive Pancreatic Surgery.

He was trained as a surgeon in Utrecht, Amsterdam, and Southampton. Marc has designed and coordinated multiple multicenter studies including randomized trials in the field of HPB surgery. He is the chair of the E-AHPBA Bilbao 2021 program committee, chair if the Innovation subcommittee of the IHPBA, chair of the scientific committee of the Dutch Pancreatic Cancer Group including the Dutch Pancreatic Cancer Audit, and a member of the scientific committee of the IHPBA. You can follow Marc on Twitter @MarcBesselink.

Demartines, N

Nicolas Demartines
Lausanne University Hospital


Professor of Surgery, and Chair Surgery at the University Hospital in Lausanne Switzerland. Member of the French Academy of Surgery in Paris, guest professor at the University Hospital of Lanzhou and honorary Fellow of the ASGBI, the Chinese College of Surgeons and the French Association of Surgery.

Focus on oncologic surgery, mainly hepato-pancreatico-biliary. Research includes innovative treatment of liver metastasis and peri-operative management (ERAS). Chair implementation of the ERAS Society. Faculty at IRCAD-EITS. Vice-Chair of the council of the Society of British Journal of Surgery. Expert at the French National Institute for Cancer (INCA).

van Dam, R

Ronald van Dam
Maastricht University Medical Center
the Netherlands



Froeling, F

Fieke Froeling
University of Glasgow
United Kingdom


I am a Consultant Medical Oncologist and Clinical Senior Lecturer at the Beatson West of Scotland Cancer Centre and University of Glasgow with a clinical and research focus on pancreatic cancer. The overall aim of my research is to develop personalised therapeutic strategies that emanate from discoveries in both basic science and reverse translation from clinical observation.


Mo Abu Hilal
Fondazione Poliambulanza



Klumpen, HJ

Heinz-Josef Klümpen
Amsterdam University Medical Centers
the Netherlands



Aug 2008 – current:       Staff member Dept Medical Oncology

Amsterdam University Medical Centers


Jan 2006 – Aug 2008:   Clinical Fellow, Medical Oncology

Dept Medical Oncology, Westmead Hospital, Westmead, Australia


Oct 03 – Dec 2005:       Medical Oncologist/Advanced Trainee, Medical Oncology

Academic Medical Centre, University of Amsterdam



Dec 1998 –Sept 2003:   Residency in Internal Medicine

University Medical Centre Utrecht


Mar 1997 –Nov 1998:    Registrar

The Netherlands Cancer Institute, Amsterdam


April 1990 –Mar 1997:   Medical School

Heinrich-Heine University, Düsseldorf, Germany



PhD graduation 21st March 2012, Title “Personalized medicine of targeted anti-cancer drugs”. Supervisors: Prof JHM Schellens, Faculty of Pharmacy, University of Utrecht



The Netherlands, BIG-number 39047488001

Australia MPO352726


Extramural Appointments:

Member of the national guideline committee for Hepatocellular carcinoma, cholangiocarcinoma

Chair of the Dutch hepatocellular & cholangiocarcinoma group (DHCG) 2014-2019

Leader of the EURACAN subdomain for cholangiocarcinoma since 2018



2000-2021: co-author of 105 publications in peer reviewed journals

Koerkamp, BG

Bas Groot Koerkamp
Erasmus MC
the Netherlands


Bas Groot Koerkamp is a surgical oncologist and transplant surgeon at Erasmus MC in Rotterdam, the Netherlands.

His main research interest is clinical and translational research in HPB oncology. He is the PI of several randomised controlled trials including the PUMP, PREOPANC-2, and PREOPANC-3 trials.

ALPS Speaker – Kwon

David Kwon
Cleveland Clinic


Dr. Kwon is currently the Director of Laparoscopic Liver Surgery at Cleveland Clinic, Cleveland, Ohio. He has finished his medical education, surgical training including fellowship in liver transplantation and hepato-pancreato-biliary surgical oncology in Korea, but has spent much time abroad so is multilingual – speaks English, French, Spanish and Korean. He built up his expertise in living donor liver transplantation (LDLT) and laparoscopic hepatectomy at Samsung Medical Center in Korea where he operated on over 700 LDLTs and over 800 purely laparoscopic liver resection. With extensive experience in both surgical arenas, he started a purely laparoscopic donor program for both pediatric and adult LDLT recipients in May 2013 and established one of the largest laparoscopic liver donor program in the world. He worked as a faculty in many advanced laparoscopic HPB workshops including IRCAD and SAGES and helped start 3 living donor liver transplant centers across Asia. He worked as a faculty for a year at Mayo Clinic Rochester before moving to Cleveland Clinic where he successfully started a laparoscopic donor program in 2018, which has grown into the largest laparoscopic donor program in US.

Marchiegiani, G

Giovanni Marchegiani
Verona Pancreas Institute


Giovanni Marchegiani is a Pancreatic Surgeon and junior faculty at the Verona Pancreas Institute of Verona University.

He holds a PhD at the Verona University and a Fellowship at the Massachusetts General Hospital of the Harvard University, both focused on Pancreatic Neoplasms. He is the coordinator of the Young pancreatologist in Europe (YOUPPIE) platform of the EPC, Editor Assistant of the BJS, faculty of the UEG and of the E AHPBA. He also serves as the secretary of the ISGPS (International Study Group in Pancreatic Surgery). He has been awarded with the “Rising Star Award 2021” of the United European Gastroenterology. He is the developer of the Icyst APP, a tool integrating the available guidelines on pancreatic cystic neoplasms of the pancreas.

Twitter: @Gio_Marchegiani and @YouppiePancreas

Naredi, P

Peter Naredi
University of Gothenburg



Peter Naredi is Professor of Surgery and Head of the Institute of Clinical Sciences at the Sahlgrenska Academy, University of Gothenburg. After defending his thesis on Tumour blood flow at the University of Gothenburg he did his postdoc at the Cancer Center, University of California, San Diego, USA. In 1997 he moved to the University of Umeå and was appointed professor of surgery in 2003.

He has specialized in cancer surgery, especially hepatopancreaticobiliary surgery and melanoma. In 2012 he moved back to the University of Gothenburg and the Sahlgrenska university hospital. His main research areas are in clinical and basic research of cancers in the liver and pancreas. He has over 160 publications in highly ranked journals as the Cell, Lancet Oncol, JCO, PNAS, Nature Med, Nature Rev Clin Oncol, Cancer Res and Clin Ca Res. Peter Naredi has been president of the European Society of Surgical Oncology (ESSO), the European Cancer Organisation (ECCO), the Swedish surgical society and the Scandinavian surgical society.

Pugh, S

Siân Pugh
Addenbrooke’s Hospital

United Kingdom


Siân’s research is focused on understanding the determinants of progression in colorectal cancer and she has a particular interest in colorectal liver metastasis. She is an investigator for the New EPOC study and has led both the latter trial logistics and translational outputs.

Originally Siân intended to combine a research career with general surgery and successfully pursued this to the level of ST4, following which she went on to secure a prestigious MRC clinical research training fellowship. She has subsequently changed her clinical focus and is currently training in medical oncology at Addenbrooke’s Hospital, Cambridge, United Kingdom.

Roberts, K

Keith Roberts
University Hospitals Birmingham NHS Foundation Trust
United Kingdom


Keith Roberts is a HPB and liver transplant surgeon in Birmingham, UK. He is the Royal College of Surgeons lead for pancreatic cancer and the Treasurer to the Pancreatic Society of Great Britain and Ireland. His research focuses upon improving pancreatic cancer pathways, pancreatic exocrine insufficiency and improving understanding of post-operative pancreatic fistula.

Wilmink, H

Hanneke Wilmink
Amsterdam University Medical Centers

the Netherlands


TBC Gastrointestinal cancer with focus on pancreatic cancer

Since my tenure as a staff member at the Amsterdam UMC (location AMC), department of medical oncology, my focus has been on pancreatic cancer. Since 2012 I am fully dedicated to this tumor type and responsible for pancreatic cancer patientcare and research within the department. My main objective is to improve the prognosis of pancreatic cancer patients through innovative clinical and translational research. The clinical trial participants as well as the existing biobank are the main source for the development and validation of prognostic and predictive markers in blood and tumor tissues. These studies are performed in multidisciplinary collaboration, which involves LEXOR, the departments of Pathology, Surgery, (Intervention)Radiology, Clinical Pharmacy, Radiotherapy and Gastroenterology. Furthermore I am active in conducting trials with innovative designs, which becomes neccesary by the changing landscape of the treatment of tumors from “one size fits all” to specific treatments of (clinically and/or molecularly-defined) subgroups. In order to continue the
support of patients at the end stage of their lives when often disabling symptoms are present, I decided to qualify as a palliative care specialist and to join the Palliative Team at the AMC. I have joined several regional/national organizations in order to contribute to the improvement of the quality of care and research on pancreatic cancer.

Metabolism and cancer
My aim is to develop new therapies with a specific focus on cancer metabolism. Cancer cell metabolism differs from healthy cell metabolism, but this difference is not yet exploited by anticancer therapies. One of the key enzymes that function at the crossroads of cellular metabolism and DNA repair is Isocitrate dehydrogenase 1/2 (IDH1/2). Mutations in IDH1/2 occur in various types of cancer, including glioma, intrahepatic cholangiocarcinoma and chondrosarcoma. My current research focuses on metabolic consequences of IDH 1/2 mutations as therapeutic targets. These studies are performed in multidisciplinary collaboration, which involves LEXOR, the departments of Pathology, Cell biology and Histology, Surgery, Clinical Pharmacy, Orthopedics and the participating research hospitals Amsterdam UMC, location VUmc, LUMC and the department of Oncology and Medicine of McGill University, Montreal Canada (prof. dr. M. Pollak).

Wilson, C

Colin Wilson
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
United Kingdom


Colin Wilson is an HPB and Transplant surgeon based in Newcastle-upon-Tyne, United Kingdom. He trained in the North East, Cambridge and Oxford and his diverse clinical practice includes all aspects of malignancy and abdominal organ transplantation. He has a specialist interest in neuroendocrine tumours and advanced reconditioning of organs for transplantation.
He leads the delivery of novel organ assessment research in abdominal organ transplantation as part of the NIHR funded Blood Transplant Research Unit based in Newcastle and Cambridge Universities. Alongside this he is part of the team delivering adjuvant and definitive ablation therapies for liver and pancreatic malignancies.

Wolfgang, C

Chris Wolfgang
NYU School of Medicine



Chief of Hepatobiliary and Pancreatic Surgery

Professor of Surgery

NYU School of Medicine and NYU Langone Health System

Back To Top